Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Papaverine with Chemoradiation for Stage II-III Non-Small Cell Lung Cancer
NCT05136846Phase 1Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of papaverine in non-small cell lung cancer (NSCLC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Maximally Tolerated Dose at 6 weeks. Started Dec 2021; status: recruiting.
02
Drugs
papaverine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05136846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136846.